0001104659-21-151405.txt : 20211220 0001104659-21-151405.hdr.sgml : 20211220 20211220070035 ACCESSION NUMBER: 0001104659-21-151405 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211220 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211220 DATE AS OF CHANGE: 20211220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 211503628 BUSINESS ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 8-K 1 tm2135883d1_8k.htm FORM 8-K
0001346830 false 0001346830 2021-12-20 2021-12-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 20, 2021

  

CARA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36279   75-3175693

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

         

4 Stamford Plaza

107 Elm Street, 9th Floor

Stamford, Connecticut

       06902
 (Address of principal executive offices)       (Zip Code)
         
Registrant's telephone number, including area code: (203) 406-3700
         

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

  

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per share CARA The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

   

 

 

Item 7.01. Regulation FD Disclosure.

 

On December 20, 2021, Cara Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Centers for Medicare & Medicaid Services (“CMS”) granted the Company’s Transition Drug Add-on Payment Adjustment (“TDAPA”) for KORSUVA™ (difelikefalin) injection (“KORSUVA injection”) in the anti-pruritic functional category.

 

A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Form 8-K and is incorporated by reference to this Item 7.01.

 

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.

 

Item 8.01. Other Events.

 

On December 20, 2021, the Company announced that CMS has granted TDAPA to KORSUVA injection in the anti-pruritic functional category. TDAPA will apply to KORSUVA beginning April 4, 2022 for two years.

 

CMS expressed in its written communication to the Cara and Vifor Pharma, a continuing interest in engaging with the companies regarding potential post-TDAPA support to ensure all beneficiaries with end-stage renal disease have access to innovative products such as KORSUVA injection.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

  

Description

   
99.1   Press Release, dated December 20, 2021.
     
104   Cover page interactive data file (formatted as Inline XBRL).

 

   

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CARA THERAPEUTICS, INC.
   
  By: /s/ THOMAS REILLY
    Thomas Reilly
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

Date: December 20, 2021

 

   

 

 EX-99.1 2 tm2135883d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

 

KORSUVA receives TDAPA reimbursement beginning April 2022

 

U.S. commercial launch on track for early second quarter 2022

 

Stamford, Conn. Dec. 20, 2021 – Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted Transitional Drug Add-On Payment Adjustment (TDAPA) to KORSUVA™ (difelikefalin) injection in the anti-pruritic functional category. TDAPA will apply to KORSUVA injection beginning April 4, 2022, for two years. KORSUVA injection was approved by the U.S. Food and Drug Administration (FDA) in August 2021 for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

 

TDAPA enables payment for new injectable end-stage renal disease (ESRD)-related therapies to be reimbursed outside of the ESRD Prospective Payment System (PPS) bundle.

 

As KORSUVA injection is just the second product to be approved for TDAPA, CMS expressed in its written communication to Cara and Vifor Pharma, Cara’s U.S. commercial partner for KORSUVA injection, a continuing interest in engaging with the companies regarding potential post-TDAPA support to ensure all beneficiaries with ESRD have access to innovative products such as KORSUVA injection.

 

“Receiving TDAPA from CMS is a crucial step toward the commercial launch of KORSUVA injection, which we believe will benefit thousands of chronic kidney disease patients undergoing dialysis who suffer from pruritus,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “We are pleased to have secured TDAPA reimbursement for KORSUVA injection and are encouraged by the willingness of CMS leadership to engage with Cara and Vifor Pharma regarding potential post-TDAPA support.”

 

"We are pleased to have secured TDAPA reimbursement in the United States for KORSUVA injection effective April 2022, and we look forward to bringing this important treatment option to the people who need it,” said Molly Painter, President USA, Vifor Pharma.

 

   

 

 

 

About Cara Therapeutics

 

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The company is developing an oral KORSUVA (difelikefalin) formulation and plans to initiate Phase 3 programs in the first quarter of 2022 for the treatment of pruritus in patients with atopic dermatitis and non-dialysis-dependent chronic kidney disease, Phase 2 trials of oral KORSUVA are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.caratherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

 

About KORSUVA™ Injection

 

KORSUVA is a kappa opioid receptor agonist developed in Cara laboratories and indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). KORSUVA Injection is not a federally controlled substance.

 

Breakthrough Therapy Designation was received from the FDA for KORSUVA Injection for the treatment of CKD-aP in HD patients and the New Drug Application was evaluated by the FDA with Priority Review.

 

Important Safety Information

 

Warnings and Precautions

 

Dizziness, Somnolence, Mental Status Changes, and Gait Disturbances: These adverse reactions, including falls, have occurred in patients taking KORSUVA and may subside with continued treatment. Concomitant use of centrally acting depressant medications, sedating antihistamines, and opioid analgesics may increase the likelihood of these adverse reactions and should be used with caution during treatment with KORSUVA.

 

Risk of Driving and Operating Machinery: Dizziness, somnolence, and mental status changes have occurred in patients taking KORSUVA. KORSUVA may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. Advise patients not to drive or operate dangerous machinery until the effect of KORSUVA on their ability to do so is known.

 

Adverse Reactions

 

The most common adverse reactions (incidence ≥2% and ≥1% higher than placebo) were diarrhea (9.0%), dizziness (6.8%), nausea (6.6%), gait disturbances, including falls (6.6%), hyperkalemia (4.7%), headache (4.5%), somnolence (4.2%), and mental status changes (3.3%).

 

Use in Specific Populations

 

Severe Hepatic Impairment: The influence of severe hepatic impairment on the pharmacokinetics of KORSUVA in subjects undergoing hemodialysis (HD) has not been evaluated; therefore, use of KORSUVA in this population is not recommended.

 

   

 

 

 

Geriatric Use: The incidence of somnolence was higher in KORSUVA-treated subjects aged 65 years and older (7.0%) than in KORSUVA-treated subjects less than 65 years of age (2.8%). The incidence was comparable in both placebo age groups (3.0% and 2.1%, respectively).

 

Indication

 

KORSUVA is indicated for the treatment of moderate to severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).

 

Limitation of Use: KORSUVA has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.

 

Please see KORSUVA™ injection full Prescribing Information at www.korsuva.com.

 

About Chronic Kidney Disease-associated Pruritus

 

CKD-aP is an intractable systemic itch condition that occurs with high frequency and intensity in patients with chronic kidney disease undergoing dialysis. Pruritus has also been reported in patients with stage III-V CKD who are not on dialysis. Aggregate, longitudinal, multi-country studies estimate the weighted prevalence of CKD-aP to be approximately 40% in patients with end-stage renal disease (ESRD), with approximately 25% of patients reporting severe pruritus. The majority of dialysis patients (approximately 60 to 70%) report pruritus, with 30 to 40% reporting moderate or severe pruritus.1,2,3 Recent data from the ITCH National Registry Study showed that among those with pruritus, approximately 59% experienced symptoms daily or nearly daily for more than a year. Given its association with CKD/ESRD, most afflicted patients will continue to have symptoms for months or years, with currently employed antipruritic treatments, such as antihistamines and corticosteroids, unable to provide consistent, adequate relief. Moderate-to-severe chronic pruritus has repeatedly been shown to directly decrease quality of life, contribute to symptoms that impair quality of life (such as poor sleep quality), and is associated with depression.4 CKD-aP is also an independent predictor of mortality among hemodialysis patients, mainly related to increased risk of inflammation and infections.

 

Forward-looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the potential timeline for launch of KORSUVA™ injection, the potential timeline for post-TDAPA reimbursement and the potential of KORSUVA™ injection to be a therapeutic option for CKD-aP in dialysis dependent patients and the potential for KORSUVA to address additional pruritic indications. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara's filings with the Securities and Exchange Commission, including the "Risk Factors" section of Cara's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Cara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

   

 

 

 

References:

 

1 Pisoni RL, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2006; 21:3495-3505.
2 Ramakrishnan K, et al. Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms. International Journal of Nephrology and Renovascular Disease. 2014; 7: 1-12.
3 Sukul et al. Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients. Kidney Med. 2020 Nov 21;3(1):42-53.
4 Mathur VS, et al. A longitudinal study of Uremic Pruritus in hemodialysis patients. Clin J Am Soc Nephrol. 2010; 5(8):1410-1419.

 

MEDIA CONTACT: INVESTOR CONTACT:
Annie Spinetta Janhavi Mohite
6 Degrees Stern Investor Relations, Inc.
973-768-2170 212-362-1200
aspinetta@6degreespr.com janhavi.mohite@SternIR.com

 

   

 

 EX-101.SCH 3 cara-20211220.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cara-20211220_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cara-20211220_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2135883d1_ex99-1img001.jpg GRAPHIC begin 644 tm2135883d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Dec. 20, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 20, 2021
Entity File Number 001-36279
Entity Registrant Name CARA THERAPEUTICS, INC.
Entity Central Index Key 0001346830
Entity Tax Identification Number 75-3175693
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4 Stamford Plaza
Entity Address, Address Line Two 107 Elm Street
Entity Address, Address Line Three 9th Floor
Entity Address, City or Town Stamford
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06902
City Area Code 203
Local Phone Number 406-3700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol CARA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2135883d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001346830 2021-12-20 2021-12-20 iso4217:USD shares iso4217:USD shares 0001346830 false 8-K 2021-12-20 CARA THERAPEUTICS, INC. DE 001-36279 75-3175693 4 Stamford Plaza 107 Elm Street 9th Floor Stamford CT 06902 203 406-3700 false false false false Common stock, par value $0.001 per share CARA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://caratherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2135883d1_8k.htm cara-20211220.xsd cara-20211220_lab.xml cara-20211220_pre.xml tm2135883d1_ex99-1.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2135883d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2135883d1_8k.htm" ] }, "labelLink": { "local": [ "cara-20211220_lab.xml" ] }, "presentationLink": { "local": [ "cara-20211220_pre.xml" ] }, "schema": { "local": [ "cara-20211220.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CARA", "nsuri": "http://caratherapeutics.com/20211220", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2135883d1_8k.htm", "contextRef": "From2021-12-20to2021-12-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://caratherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2135883d1_8k.htm", "contextRef": "From2021-12-20to2021-12-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-151405-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-151405-xbrl.zip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end